RecoveryPlus.health is a remote cardiac rehabilitation platform that utilizes an FDA-listed telehealth system to deliver tailored exercise plans and care management for patients with chronic heart conditions. This service significantly reduces hospital readmission rates to 2% and enhances patient compliance to over 90%, compared to traditional rehab methods.

Signet Therapeutics develops targeted therapeutics that employ precision medicine techniques to identify and inhibit specific pathways in cancer cells. The company provides personalized treatment options for patients with various cancer types, addressing the limitations of traditional therapies.

Cure Genetics develops cell and gene therapies utilizing AIMS CAR-NKT and VELPTM AAV platforms to target solid tumors and genetic diseases. The company addresses the need for effective treatments in oncology and complex genetic disorders through its differentiated therapeutic pipeline and global collaborations.